Table 3 Prevalence of sarcopenia and sarcopenia categories according to BIS eGFR (ml/min/1.73m2) categories
|  | Non-sarcopenic (n = 1270) | Sarcopenic (n = 150) | p-value | ||
|---|---|---|---|---|---|
BIS eGFR category | No sarcopenia (n = 1114) | Probable sarcopenia (n = 156) | Confirmed sarcopenia (n = 65) | Severe sarcopenia (n = 85) | |
≥90 (n = 9) | 6 (66.7%) | 3 (33.3%) | 0.026 | ||
3 (33.3%) | 3 (33.3%) | 2 (22.2%) | 1 (11.1%) | Â | |
60–89 (n = 538) | 483 (89.8%) | 55 (10.2%) | 0.745 | ||
440 (81.8%) | 43 (8.0%) | 26 (4.8%) | 29 (5.4%) | Â | |
45–59 (n = 542) | 496 (91.5%) | 46 (8.5%) | 0.046 | ||
436 (80.4%) | 60 (11.1%) | 25 (4.6%) | 21 (3.9%) | Â | |
30–44 (n = 259) | 225 (86.9%) | 34 (13.1%) | 0.138 | ||
188 (72.6%) | 37 (14.3%) | 10 (3.9%) | 24 (9.3%) | Â | |
15–29 (n = 72) | 60 (83.3%) | 12 (16.7%) | 0.084 | ||
47 (65.3%) | 13 (18.1%) | 2 (2.8%) | 10 (13.9%) | Â | |
≥60 (n = 1089) | 985 (90.4%) | 104 (9.6%) | 0.024 | ||
879 (80.7%) | 106 (9.7%) | 53 (4.9%) | 51 (4.7%) | ||
< 60 (n = 331) | 285 (86.1%) | 46 (13.9%) | |||
235 (71.0%) | 50 (15.1%) | 12 (3.6%) | 34 (10.3%) | ||